Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SAVA Cassava Sciences Inc

Trading 02-24 13:36:16 EST

2.42

+0.26

+12.04%

High2.47	Low2.14	Vol1.64M
Open2.17	D1 Closing2.16	Amplitude15.27%
Mkt Cap116.91M	Tradable Cap105.21M	Total Shares48.31M
T/O3.89M	T/O Rate3.78%	Tradable Shares43.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SAVA","market":"US","secType":"STK","nameCN":"Cassava Sciences Inc","latestPrice":2.42,"timestamp":1771958171892,"preClose":2.16,"halted":0,"volume":1644812,"delay":0,"changeRate":0.12037037037037027,"floatShares":43475193,"shares":48307896,"eps":-2.197613,"marketStatus":"Trading","change":0.26,"latestTime":"02-24 13:36:16 EST","open":2.17,"high":2.4699,"low":2.14,"amount":3885428.6917524,"amplitude":0.152731,"askPrice":2.43,"askSize":500,"bidPrice":2.42,"bidSize":1196,"shortable":3,"etf":0,"ttmEps":-2.197613,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771966800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.16,"preHourTrading":{"tag":"盘前","latestPrice":2.16,"preClose":2.16,"latestTime":"09:29 EST","volume":885,"amount":1904.0566139999999,"timestamp":1771943354607,"change":0,"changeRate":0,"amplitude":0.036759},"postHourTrading":{"tag":"盘后","latestPrice":2.15,"preClose":2.16,"latestTime":"19:42 EST","volume":4077,"amount":8775.3425,"timestamp":1771893741656,"change":-0.01,"changeRate":-0.00463,"amplitude":0.00463},"volumeRatio":4.39853,"impliedVol":1.2947,"impliedVolPercentile":0.7769},"requestUrl":"/m/hq/s/SAVA/wiki","defaultTab":"wiki","newsList":[{"id":"2613278470","title":"Ensysce Biosciences Executives to Present at USASP Annual Scientific Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2613278470","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613278470?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:01","pubTimestamp":1771851690,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences Executives to Present at USASP Annual Scientific Meeting               Ensysce Biosciences (NASDAQ: ENSC) said its executives have been invited to participate in several upcoming s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL5hSQ6b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENSC","SAVA","BK4588","BK4547","BK4007","BK4585","EVT.AU","BK7035"],"gpt_icon":0},{"id":"2612283920","title":"Cassava Sciences DOJ Inquiry Closed, Legal Overhang Eased","url":"https://stock-news.laohu8.com/highlight/detail?id=2612283920","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612283920?lang=en_us&edition=fundamental","pubTime":"2026-02-19 22:18","pubTimestamp":1771510727,"startTime":"0","endTime":"0","summary":"The latest update is out from Cassava Sciences ( ($SAVA) ). On February 19, 2026, Cassava Sciences announced that the U.S. Department of Justice Fr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cassava-sciences-doj-inquiry-closed-legal-overhang-eased?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cassava-sciences-doj-inquiry-closed-legal-overhang-eased?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SAVA","BK4585","BK4588","BK4547","BK4007"],"gpt_icon":0},{"id":"2612138288","title":"BUZZ-Cassava Sciences rises after US DOJ closes probe into company","url":"https://stock-news.laohu8.com/highlight/detail?id=2612138288","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612138288?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:54","pubTimestamp":1771509267,"startTime":"0","endTime":"0","summary":"BUZZ-Cassava Sciences rises after US DOJ closes probe into company** Shares of drug developer Cassava Sciences SAVA.O rise 2.82% to $2.19 premarket** Co says the U.S. Department of Justice has ended its probe into the company regarding allegations of research misconduct for its experimental Alzheimer's drug simufilam** Co says probe ended four months after the Justice Department dismissed a criminal indictment accusing former adviser Hoau-Yan Wang, who allegedly submitted false data regarding the drug** SAVA shares fell 16.1% in 2025   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nL4N3ZF129:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SAVA","BK4588","BK4547","BK4007"],"gpt_icon":0},{"id":"2612407776","title":"Cassava Sciences Says DOJ Closes Investigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2612407776","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612407776?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:00","pubTimestamp":1771506023,"startTime":"0","endTime":"0","summary":"Cassava Sciences said the U.S. Department of Justice has closed its inquiry into the company tied to allegations of research misconduct, following the dismissal with prejudice of the related indictment in October 2025. The company also noted it previously settled negligence-based disclosure charges with the U.S. Securities and Exchange Commission in September 2024, paying a monetary penalty without admitting or denying the allegations, and said the DOJ and SEC matters are now resolved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire  on February 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL4vdDqn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2095319765.USD","SG9999014021.USD","IE00B3QW5Z07.USD","NDAQ","BK4585","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","BK4112","SAVA","BK4547","BK4007","IE00B64PRP62.GBP","LU0314104364.USD","IE00BKPKM429.USD","BK4588","LU2210149790.SGD"],"gpt_icon":0},{"id":"2612072054","title":"Cassava Sciences Inc - Indictment Dismissed With Prejudice by DOJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2612072054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612072054?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:00","pubTimestamp":1771506004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA8MTCLH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SAVA","BK4588","BK4585","BK4547","BK4007"],"gpt_icon":0},{"id":"2612283325","title":"Cassava Announces Closure of U.S. Department of Justice Investigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2612283325","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612283325?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:00","pubTimestamp":1771506000,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, Feb.  19, 2026  (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/19/3241037/8339/en/Cassava-Announces-Closure-of-U-S-Department-of-Justice-Investigation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","CNS","BK4585","BK4547","SAVA","BK4007","BK4588"],"gpt_icon":0},{"id":"2610501950","title":"Cassava Sciences And 2 Other Promising Penny Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2610501950","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610501950?lang=en_us&edition=fundamental","pubTime":"2026-02-12 01:05","pubTimestamp":1770829548,"startTime":"0","endTime":"0","summary":"As February begins, major U.S. stock indexes have shown a strong start, with the Dow Jones Industrial Average adding 515 points and the S&P 500 nearing record highs. In this context of market optimism, investors may find interest in exploring penny stocks—an investment area that often involves smaller or newer companies. Although the term \"penny stocks\" might seem outdated, these investments can still offer surprising value and potential for growth when backed by solid financial health.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3112800-choice2-main-header/1585186996564","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3112800-choice2-main-header/1585186996564"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/consumer-services/nasdaq-sda/suncar-technology-group/news/cassava-sciences-and-2-other-promising-penny-stocks","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/consumer-services/nasdaq-sda/suncar-technology-group/news/cassava-sciences-and-2-other-promising-penny-stocks","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4023","BK4113","CRCT","BK4183","BABB","BK4551","BK4180","BK4173","BK4209","LU1046422090.SGD","BK4579","BK4547","BK4204","DDL","LCUT","BK4161","LX","MAPS","NEPH","BK4007","BK4588","SAVA","UDMY","LU0049112450.USD","BK4166","LFVN","WDH","BK4531","BK4539","SDA","BK4192","BK4585","LU1235295612.USD","BK4191","BK4509"],"gpt_icon":0},{"id":"2603684212","title":"Cassava Sciences announces publication of Phase 3 results for simufilam","url":"https://stock-news.laohu8.com/highlight/detail?id=2603684212","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603684212?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:10","pubTimestamp":1768309841,"startTime":"0","endTime":"0","summary":"Cassava Sciences (SAVA) announced publication of the article Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s diseas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cassava-sciences-announces-publication-of-phase-3-results-for-simufilam-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cassava-sciences-announces-publication-of-phase-3-results-for-simufilam-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BK4007","BK4547","SAVA"],"gpt_icon":0},{"id":"2603875684","title":"Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2603875684","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603875684?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309200,"startTime":"0","endTime":"0","summary":"As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ stud","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3217761/8339/en/Cassava-Announces-Publication-of-Peer-Reviewed-Phase-3-Results-for-Simufilam-in-Alzheimer-s-Disease-in-the-Journal-of-Prevention-of-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4601","BK4135","BK4007","BK4585","SAVA","BK4547","ETH","CNS","BK4588"],"gpt_icon":0},{"id":"2595790834","title":"SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2595790834","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595790834?lang=en_us&edition=fundamental","pubTime":"2025-12-30 21:17","pubTimestamp":1767100620,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Dec.  30, 2025  (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (\"NeuroThera\"), a clinical-stage p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/30/3211377/0/en/SciSparc-Neurothera-Labs-Granted-Patent-by-Israeli-Patent-Office-for-its-Proprietary-Opioid-Based-Patent-Family-to-Enhance-Pain-Relief-and-Reduce-Side-Effects.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAVA","BK4588","BK4585","BK4007","BK4547"],"gpt_icon":0},{"id":"2593904574","title":"Cassava Sciences Inc: Will Pay $31.25 Mln for Complete Settlement and Release of All Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2593904574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593904574?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:00","pubTimestamp":1766494859,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT02P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SAVA","BK4585","BK4007","BK4547","BK4588"],"gpt_icon":0},{"id":"2593449042","title":"Cassava Sciences: to Resolve Litigation Filed in US District Court in Texas","url":"https://stock-news.laohu8.com/highlight/detail?id=2593449042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593449042?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:00","pubTimestamp":1766494859,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT02P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4007","BK4588","SAVA","BK4547"],"gpt_icon":0},{"id":"2593049049","title":"Cassava Sciences Settles Securities Class Action for $31.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2593049049","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593049049?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:00","pubTimestamp":1766494834,"startTime":"0","endTime":"0","summary":"Cassava Sciences Inc. has reached a definitive agreement to settle a consolidated securities class action litigation filed in 2021 in the United States District Court for the Western District of Texas. The company will pay $31.25 million to resolve all claims from plaintiffs who purchased or acquired Cassava common stock or call options, or sold put options, between September 14, 2020, and October 12, 2023. The settlement fully releases Cassava from all related claims and does not constitute an admission of fault or wrongdoing. The company had previously reserved the entire settlement amount as a loss contingency in the second quarter of 2025. With the settlement, Cassava plans to focus on developing simufilam for TSC-related epilepsy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL62WWsd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00BGHQF748.EUR","SAVA","SG9999014039.USD","LU2210150020.SGD","BK4547","SG9999014021.USD","BK4007","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4585","NDAQ","LU0314104364.USD","BK4112","SG9999014013.SGD","BK4588","LU2095319765.USD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2593854418","title":"Cassava Announces Agreement to Settle Securities Class Action Litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2593854418","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593854418?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:00","pubTimestamp":1766494800,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, Dec.  23, 2025  (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/23/3209829/8339/en/Cassava-Announces-Agreement-to-Settle-Securities-Class-Action-Litigation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAVA","BK4585","BK4588","CNS","BK4547","BK4135","BK4007"],"gpt_icon":0},{"id":"2593458615","title":"Cassava Sciences Names Dawn C. Bir to Compensation Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2593458615","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593458615?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:10","pubTimestamp":1766437810,"startTime":"0","endTime":"0","summary":"Cassava Sciences Inc. has amended its previous filing to announce that on December 18, 2025, Dawn C. Bir was appointed as a member of the Board’s Compensation Committee, effective immediately. This update corrects the earlier report, which did not include her committee assignment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL6TPx78:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SAVA","BK4588","BK4547","BK4007"],"gpt_icon":0},{"id":"2592987061","title":"Correction: Investors Hope for Rate Cut Following Subdued Inflation as US Futures Mixed in Friday's Premarket Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2592987061","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592987061?lang=en_us&edition=fundamental","pubTime":"2025-12-19 22:49","pubTimestamp":1766155771,"startTime":"0","endTime":"0","summary":"(Corrects the third paragraph to note the personal income and outlays report being rescheduled.)US stock futures were mixed in Friday's premarket session, with investors hopeful of a federal rate cut ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a9f9ae861e0d5137ca1db9f83a4575ef","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SAVA","UDOW","DOG","BK4190","BK4139","BK4211","HOPE","ISBC","PSQ","BK4116",".SPX","BK4547","QID","WYFI","BK4007","NVIW.SI","BK4585","MGRT","TSYW.SI",".DJI","SQQQ","USAW.SI","DJX","MNQmain","PBM","USJW.SI","VMAR","DDM","TQQQ","YCBD","DXD","MYMmain","BK4588","NQmain","SDOW",".IXIC","QLD"],"gpt_icon":1},{"id":"2592180462","title":"Stocks to Watch: Nike, Cassava Sciences, KB Home","url":"https://stock-news.laohu8.com/highlight/detail?id=2592180462","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592180462?lang=en_us&edition=fundamental","pubTime":"2025-12-19 07:39","pubTimestamp":1766101140,"startTime":"0","endTime":"0","summary":"Nike recorded a lower profit and said it expects revenue to a decline in its current quarter. The stock fell 11% to $58.62 in after-hours trading Thursday.Cassava Sciences said the FDA had placed a hold on its trial for a drug to treat epilepsy. Shares slid 13% to $2.49 after the bell.KB Home delivered fewer homes and recorded a lower profit in its most recent quarter. The stock declined 3.6% to $60.50.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0128525929.USD","LU0786609619.USD","BK4585","BK4007","IE00BFXG0V08.USD","NKE","BK4533","LU1267930573.SGD","LU0310800379.SGD","BK4146","LU1303367103.USD","BK4534","BK4561","LU0889566641.SGD","LU0708994859.HKD","BK4207","BK4558","KBH","LU1267930813.SGD","BK4088","BK4547","LU0823411888.USD","LU0792757196.USD","BK4588","IE00BYQQ9H92.USD","BK4581","LU0029864427.USD","LU2098885051.SGD","SAVA","KB"],"gpt_icon":1},{"id":"2592618256","title":"Cassava Sciences Inc - on Dec 15, FDA Places Full Clinical Hold on Cassava's Trial - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2592618256","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592618256?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:04","pubTimestamp":1766095454,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO18P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4007","BK4588","SAVA","BK4547"],"gpt_icon":0},{"id":"2592182683","title":"Cassava Sciences: Not Expected to Initiate Proof-of-Concept Clinical Trial for Simufilam in Tsc-Related Epilepsy in H1 2026 as Previously Disclosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2592182683","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592182683?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:04","pubTimestamp":1766095454,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO18P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","BK4547","SAVA","BK4007"],"gpt_icon":0},{"id":"2592182530","title":"FDA Puts Cassava Sciences Simufilam Trial on Full Clinical Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2592182530","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592182530?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:03","pubTimestamp":1766095387,"startTime":"0","endTime":"0","summary":"Cassava Sciences Inc. is facing a regulatory setback after the U.S. Food and Drug Administration  placed a full clinical hold on its proposed proof-of-concept clinical trial for simufilam in tuberous sclerosis complex -related epilepsy. The FDA requires Cassava to provide additional pre-clinical data and modify the trial protocol before the hold can be lifted. As a result, the company no longer expects to begin the clinical trial in the first half of 2026, and the revised timeline will depend on how quickly Cassava can address the FDA’s concerns and complete the regulatory review process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via EDGAR, the E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL4hX68f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4007","BK4588","BK4585","SAVA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cassavasciences.com","stockEarnings":[{"period":"1week","weight":0.0335},{"period":"1month","weight":-0.0182},{"period":"3month","weight":-0.2895},{"period":"6month","weight":-0.0649},{"period":"1year","weight":-0.1529},{"period":"ytd","weight":0.0909}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.576923,"avgChangeRate":0.143985},{"month":2,"riseRate":0.461538,"avgChangeRate":0.029638},{"month":3,"riseRate":0.44,"avgChangeRate":0.008402},{"month":4,"riseRate":0.6,"avgChangeRate":0.05975},{"month":5,"riseRate":0.44,"avgChangeRate":0.038503},{"month":6,"riseRate":0.44,"avgChangeRate":-0.019669},{"month":7,"riseRate":0.48,"avgChangeRate":0.007146},{"month":8,"riseRate":0.5,"avgChangeRate":0.01628},{"month":9,"riseRate":0.615385,"avgChangeRate":0.114687},{"month":10,"riseRate":0.423077,"avgChangeRate":-0.039373},{"month":11,"riseRate":0.576923,"avgChangeRate":-0.009282},{"month":12,"riseRate":0.346154,"avgChangeRate":0.016148}],"exchange":"NASDAQ","name":"Cassava Sciences Inc","nameEN":"Cassava Sciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cassava Sciences Inc(SAVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cassava Sciences Inc,SAVA,Cassava Sciences Inc股票,Cassava Sciences Inc股票老虎,Cassava Sciences Inc股票老虎国际,Cassava Sciences Inc行情,Cassava Sciences Inc股票行情,Cassava Sciences Inc股价,Cassava Sciences Inc股市,Cassava Sciences Inc股票价格,Cassava Sciences Inc股票交易,Cassava Sciences Inc股票购买,Cassava Sciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cassava Sciences Inc(SAVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction